Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

IGM Biosciences Inc (IGMS)

NASDAQ
Currency in USD
9.89
-0.28(-2.71%)
Real-time Data
IGMS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Unlock Value
Day's Range
9.8010.57
52 wk Range
5.5822.50
Key Statistics
Edit
Prev. Close
10.16
Open
10.17
Day's Range
9.8-10.57
52 wk Range
5.58-22.5
Volume
52.02K
Average Volume (3m)
311.48K
1-Year Change
52.78%
Book Value / Share
1.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IGMS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Buy
Price Target
19.73
Upside
+99.49%
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 13
Quickly burning through cash
Unlock InvestingPro

IGM Biosciences Inc News & Analysis

Show more

IGM Biosciences Inc Company Profile

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
224
Market
United States

IGM Biosciences Inc SWOT Analysis

Autoimmune Pivot
IGM Biosciences shifts focus to autoimmune diseases, discontinuing oncology programs to streamline operations and concentrate on promising T-cell engagers
Pipeline Potential
Explore imvotamab's progress in rheumatoid arthritis and other autoimmune indications, with trials expanding and data readouts anticipated as key catalysts
Market Outlook
Analyst price targets range from $17 to $20, reflecting cautious optimism about IGM's strategic shift and potential in the competitive autoimmune market
Future Prospects
Learn how positive trial results could position IGM as a contender in autoimmune treatments, potentially leading to partnerships and validating their novel approach
Read full SWOT analysis

Compare IGMS to Peers and Sector

Metrics to compare
IGMS
Peers
Sector
Relationship
P/E Ratio
−2.6x−1.5x−0.6x
PEG Ratio
−0.11−0.010.00
Price/Book
7.3x0.9x2.6x
Price / LTM Sales
198.7x10.6x3.2x
Upside (Analyst Target)
96.9%300.5%46.2%
Fair Value Upside
Unlock18.9%7.0%Unlock

Analysts' Recommendations

6 Buy
4 Hold
1 Sell
Ratings:
11 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19.73

(+99.47% Upside)

More details

People Also Watch

Nano Nuclear Energy
22.71
NNE
-10.06%
Core Scientific
15.710
CORZ
-2.06%
Applied Therapeutics
1.215
APLT
-2.02%
Root
85.70
ROOT
-6.68%
GigaCloud Technology
21.84
GCT
-5.70%

FAQ

What Is the IGM Biosciences (IGMS) Stock Price Today?

The IGM Biosciences stock price today is 9.89

What Stock Exchange Does IGM Biosciences Trade On?

IGM Biosciences is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for IGM Biosciences?

The stock symbol for IGM Biosciences is "IGMS."

What Is the IGM Biosciences Market Cap?

As of today, IGM Biosciences market cap is 583.94M.

What is IGM Biosciences Earnings Per Share?

The IGM Biosciences EPS is -3.65.

What Is the Next IGM Biosciences Earnings Date?

IGM Biosciences will release its next earnings report on Mar 26, 2025.

From a Technical Analysis Perspective, Is IGMS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.